Reference check: November 7, 2026 · AI-assisted original research guidance · No human author or editorial approval claimed.
Global laboratory research should follow the entity, work and applicable requirements rather than use nationality as a shortcut. China, India, Europe and Southeast Asia belong in the same evidence-led industry lens as other markets. This guide offers a cross-border research method, not market-size estimates, growth rankings or a claim that every destination accepts the same test report.
What the primary records support
ILAC's signatory-search interface lists China National Accreditation Service for Conformity Assessment (CNAS) among selectable accreditation bodies.[1]
Evidence limit: A directory entry alone does not prove recognition for every activity, accreditation of any particular laboratory or acceptance by a destination regulator. CNAS accreditation and CMA qualification must not be treated as interchangeable.
Element's historical announcement says Temasek completed its acquisition from Bridgepoint, following the January 25, 2022 announcement.[2]
Evidence limit: A company release is attributed transaction evidence, not an independent valuation. It does not establish current ownership indefinitely or support an invented price or multiple.
01 / analytical method
Recognition is not universal market access
Start with the accreditation body, relevant arrangement and laboratory-specific scope. Then check the destination regulator and client's requirements. The ILAC directory is a live reference, not proof of every laboratory's status or automatic regulatory acceptance. Record when a status was checked and avoid extending one activity's recognition to all work a company performs.
- Which record covers the actual laboratory, site and activity?
- What additional destination-specific requirement remains unresolved?
02 / analytical method
China: keep CNAS and CMA distinct
Do not relabel CNAS accreditation as CMA qualification or assume either establishes the other. A China-specific service claim needs the applicable official record and scope; this page does not assert that a named laboratory holds either status. Distinguish status restrictions, suspension and withdrawal using original notices. National origin alone is never evidence of poor quality or laboratory risk.
- Which qualification is actually claimed and documented?
- What is the scope and current status of that specific claim?
03 / analytical method
Cross-border acquisitions and service networks
A historical international acquisition can establish a dated ownership event, not a permanent current ownership conclusion. For each transaction, separate target locations, buyer headquarters and service markets. Do not infer the transfer of every authorization, customer relationship or capability from closing. Use investor timelines as research leads and update current claims from subsequent primary records.
- Where are the affected operating sites, not just the buyer's headquarters?
- Which authorizations or contracts need separate checking after a change?
04 / analytical method
Commercial and captive capacity: compare the actual work
Compare independent networks and captive laboratories using the same workflow, evidence standard and operating assumptions. Ask about sample logistics, turnaround definitions, result requirements, responsibility and continuity. These questions apply across regions; they are not country rankings. Do not invent growth rates, capacity estimates or quality scores to fill a sparse market map.
- Is the comparison between equivalent services and scopes?
- Which claims are sourced facts, company statements or analytical assumptions?
Full primary references
- [1] MRA Signatory Search · ILAC · Undated dynamic directory; status is date-sensitive · Source checked 2026-11-07.
https://ilac.org/signatory-search/ - [2] Element announces completion of its acquisition by Temasek · Element Materials Technology · Page labelled last edited July 5, 2022; separate original publication timestamp not established · Source checked 2026-11-07.
https://www.element.com/about-element/news/2022/07/05/element-announces-completion-of-its-acquisition-by-temasek
Dates describe the original record or its stated revision, not a new event. Source checking is not legal advice, product certification, plagiarism clearance or human editorial approval. Editorial standards · Send a documented correction.